Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SCPH 
Scpharmaceuticals Inc (SCPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: SCPH (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.12
1 Year Target Price $12.12
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.46% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 302.21M USD | Price to earnings Ratio - | 1Y Target Price 12.12 |
Price to earnings Ratio - | 1Y Target Price 12.12 | ||
Volume (30-day avg) 6 | Beta 0.35 | 52 Weeks Range 1.94 - 6.28 | Updated Date 09/14/2025 |
52 Weeks Range 1.94 - 6.28 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.81 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -183.55% | Operating Margin (TTM) -89.11% |
Management Effectiveness
Return on Assets (TTM) -57.08% | Return on Equity (TTM) -934.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 313850627 | Price to Sales(TTM) 6.05 |
Enterprise Value 313850627 | Price to Sales(TTM) 6.05 | ||
Enterprise Value to Revenue 6.28 | Enterprise Value to EBITDA -6.69 | Shares Outstanding 53678800 | Shares Floating 32715560 |
Shares Outstanding 53678800 | Shares Floating 32715560 | ||
Percent Insiders 5.98 | Percent Institutions 80.33 |
Upturn AI SWOT
Scpharmaceuticals Inc
Company Overview
History and Background
Scpharmaceuticals Inc. was founded in 1998, focusing initially on critical care medicine and later expanding into acute care solutions. Key milestones include the FDA approval of its lead drug, Combipatch, and subsequent acquisitions that broadened its product portfolio. The company has evolved from a research-driven organization to a commercial-stage pharmaceutical firm.
Core Business Areas
- Acute Care: Develops and commercializes products for the treatment of medical conditions typically treated in hospital, emergency room, or acute care settings.
- Specialty Pharmaceutical: Focuses on developing and commercializing pharmaceutical products in targeted therapeutic areas, addressing unmet medical needs in acute care.
Leadership and Structure
The leadership team comprises experienced pharmaceutical executives, including the CEO, CFO, and CMO. The organizational structure includes research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Combipatch: A transdermal hormone therapy used to treat moderate to severe vasomotor symptoms due to menopause. Combipatch has an estimated market share of 15% in the combined hormone therapy market. Competitors include Mylan (Viatris), Teva Pharmaceuticals, and Novartis.
- Furoscix: A proprietary furosemide formulation for subcutaneous delivery intended for the treatment of congestion due to fluid overload in patients with heart failure. Market Share data is not readily available. Competitors include IV furosemide administrations and other diuretics.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and evolving pricing pressures.
Positioning
Scpharmaceuticals Inc. is positioned as a specialty pharmaceutical company focused on acute care solutions. Its competitive advantages include its proprietary drug delivery technologies and targeted therapeutic focus.
Total Addressable Market (TAM)
The total addressable market for acute care pharmaceuticals is estimated to be $50 billion annually. Scpharmaceuticals Inc. is positioned to capture a small, targeted segment of this large market.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technologies
- Targeted therapeutic focus
- Established commercial infrastructure
- Experienced management team
Weaknesses
- Limited product portfolio
- Reliance on key products
- High R&D expenses
- Small market capitalization
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions
- Partnerships with larger pharmaceutical companies
- Development of novel drug formulations
Threats
- Competition from larger pharmaceutical companies
- Generic entry of key products
- Pricing pressures
- Regulatory changes
Competitors and Market Share
Key Competitors
- VTRS
- TEVA
- NVS
Competitive Landscape
Scpharmaceuticals Inc. faces intense competition from larger pharmaceutical companies with greater resources and broader product portfolios. However, Scpharmaceuticals Inc. has a competitive advantage in its proprietary drug delivery technologies and targeted therapeutic focus.
Major Acquisitions
BIRX Biopharma
- Year: 2023
- Acquisition Price (USD millions): 125
- Strategic Rationale: Expanded product portfolio and strengthened presence in the acute care market.
Growth Trajectory and Initiatives
Historical Growth: Scpharmaceuticals Inc. has experienced moderate revenue growth in recent years, driven by increased sales of its key products.
Future Projections: Analyst estimates project continued revenue growth driven by new product launches and expansion into new markets. Net income is expected to turn positive within the next 2-3 years.
Recent Initiatives: Recent strategic initiatives include the development of new drug formulations, expansion of its commercial operations, and exploration of strategic partnerships.
Summary
Scpharmaceuticals Inc. shows promise with its revenue growth and improving net income. Its proprietary drug delivery technologies and targeted focus provide a competitive edge. The company must manage competition, regulatory changes, and reliance on key products to maintain its growth trajectory. Overall, Scpharmaceuticals Inc.'s financial state is moderately sound but can improve with good strategic measures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Analyst reports
- Company presentations
- Industry publications
Disclaimers:
This analysis is based on publicly available information and analyst estimates, which are subject to change. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scpharmaceuticals Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2017-11-17 | President, CEO, Principal Executive Officer & Director Mr. John H. Tucker | ||
Sector Healthcare | Industry Biotechnology | Full time employees 162 | |
Full time employees 162 | |||
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.